Our Company

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease.

NEATstik®, a rapid test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.  This achievement follows on from the launch of the ProteaseTag® Active Neutrophil Elastase Immunoassay in 2016.  A range of other laboratory-based immunoassays and point-of-care tests designed for routine monitoring of chronic diseases are in development.

ProAxsis also offers a highly experienced team who can provide clinical trial support services in regard to the specific measurement of active proteases and other inflammatory biomarkers within clinical samples.  

ProAxsis was founded in August 2013 by Professor Brian Walker and Dr Lorraine Martin, School of Pharmacy, Queen’s University Belfast. By September, ProAxsis had won the overall Northern Ireland Science Park’s 25K Award for entrepreneurialism and in February 2014, the first seed investment from partners NetScientific plc and QUBIS Ltd was secured. In September 2014, they were the first company in Northern Ireland to win a prestigious Horizon 2020 SME Instrument Award.